News

Liliana Werner, MD, PhD, joins Douglas D. Koch, MD, for a discussion on the properties, limitations, and future of IOL materials

Transient vision loss may foreshadow stroke or heart events; study urges urgent 90-day evaluation and long-term cardiovascular monitoring.

Three cases illustrate how earlier, proactive intervention can reduce medication burden and preserve vision across a range of glaucoma severity.

Two years after LASIK, hidden corneal nerve loss and immune activation persist, with higher IL‑16 and faster T‑cell motion despite normal exams.

Swiss regulator backs tinlarebant for Stargardt as DRAGON phase 3 shows slower retinal atrophy, bringing first treatment closer to patients.

Investigators noted the patient's symptoms "reliably abated when she played the oboe or when she sang, only to return immediately after stopping.”

The app is designed to improve confidence among neurology and ophthalmology trainees.

Sunil S. Patel, MD, PhD, of the University of Texas Southwestern Medical Center, breaks down QA102's first-in-class mechanism targeting harmful gut bacteria and retinal inflammation, what the phase 2 drusen volume and GA growth rate data reveal about the therapy's potential, and what a phase 3 program must address to bring an oral AMD treatment to patients without options.

Biogen buys Apellis, taking over Syfovre for geographic atrophy—what it means for GA care, trial data, safety signals, and future formulations.

Danish JAMA Dermatology trials show short-term topical or oral corticosteroids don’t raise intraocular pressure, easing glaucoma worries in atopic dermatitis care.

Siegfried G. Priglinger, MD, FEBO, weighs in on the emerging rationale for gas-free, position-free macular hole surgery using an ILM flap.

New Turkish study links sleeve gastrectomy weight loss to clearer cornea and lens, lower eye pressure, and widened anterior chamber in 6 months.

Patricio G. Schlottmann, MD, examines why injection frequency drives treatment failure in wet AMD and the particular challenges facing patients in Latin America.

Caveolin‑1 is a membrane-associated protein expressed in many cell types that plays a key role in modulating inflammatory signaling.

Victor M. Villegas, MD, discusses supraorbital vibration as an adjunct to topical anesthesia in a high-volume retina practice.

Posture, operating room setup, and small workflow adjustments can reduce cumulative neck and back strain over time.

Jay Chhablani, MD, on multimodal imaging, OCT biomarkers, and the importance of early diagnosis as treatment options emerge

Two leading retinal specialists break down MCO-010's 3-year efficacy and safety data, the significance of contralateral eye findings, and how this gene-agnostic optogenetic approach could fill a critical gap for patients with advanced inherited retinal degeneration who have limited treatment options.

Jay Chhablani, MD, a retina specialist from UPMC Vision Institute and director of the Choroidal Analysis and Research Lab at the University of Pittsburgh, discussed recent advancements in choroidal imaging.

Matias Iglicki, MD, PhD, discusses why internal limiting membrane peeling deserves greater consideration in carefully selected patients with DME.

Uveitis expert Nisha Acharya, recipient of ARVO’s Mildred Weisenfeld Award, discusses how clinical trials and big data are reshaping treatment, vaccination, and vision outcomes.

Charlie Zhang, MD, reflects on the rising incidence, diagnostic challenges, and multidisciplinary management of immune checkpoint inhibitor–associated uveitis.

Wireless brain implant taps visual cortex to deliver artificial sight, marking third successful surgery and recruiting volunteers for trials.

Avacincaptad pegol may help preserve driving-related vision in geographic atrophy, but post hoc data did not reach statistical significance.

Paul Nderitu discusses Global RETFound, a diverse, worldwide retinal AI model that outperforms existing tools and sets a new standard for equitable, open-access medical AI.

NYU researchers discuss using CellChek C widefield specular microscopy to visualize and quantify corneal nerves in dry eye disease, revealing reduced nerve fiber length and inferior whorl changes and offering a practical alternative to in vivo confocal imaging.

Data presented at ARVO 2026 show that high-dose gene therapy boosts central retinal sensitivity in X-linked retinitis pigmentosa, with the phase 3 VISTA study fully enrolled.

At ARVO Michael Siatkowski, MD, and Jody Summers, PhD, stopped to discuss the rising rates of myopia in children and if anti-inflammatory drugs could play a role in slowing progression.